Next Article in Journal
Trusted Sources of COVID-19 Vaccine Information by County Characteristics in North Carolina
Previous Article in Journal
Liver Safety Assessment of an Indonesian Hexavalent Vaccine Candidate Through Histopathology and ALT/AST Evaluation in Rats and Rabbits
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Wang et al. Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Vaccines 2025, 13, 1024

1
Henan Centers for Disease Control and Prevention, Zhengzhou 450046, China
2
Sinovac Holding Group Co., Ltd., Beijing 100085, China
3
Sinovac (Dalian) Vaccine Technology Co., Ltd., Dalian 116620, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Vaccines 2026, 14(1), 95; https://doi.org/10.3390/vaccines14010095
Submission received: 10 December 2025 / Accepted: 12 January 2026 / Published: 20 January 2026
There was an error in the original publication [1]. In the Materials and Methods, Section 2.3 “Vaccines”, the potency of the varicella vaccine (VarV) was mistakenly reported as “approximately 2.2 lgPFU per dose (0.5 mL)”, which does not reflect the release specification of the investigational product used in this study. Therefore, the sentence “The potency of the VarV was approximately 2.2 lgPFU per dose (0.5 mL)” should be corrected to “The potency of the VarV was not less than 3.3 lgPFU per dose (0.5 mL).”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Wang, Y.; Lei, X.; Huang, L.; Ma, Y.; Yuan, H.; Zhao, D.; Meng, F. Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Vaccines 2025, 13, 1024. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wang, Y.; Lei, X.; Huang, L.; Ma, Y.; Yuan, H.; Zhao, D.; Meng, F. Correction: Wang et al. Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Vaccines 2025, 13, 1024. Vaccines 2026, 14, 95. https://doi.org/10.3390/vaccines14010095

AMA Style

Wang Y, Lei X, Huang L, Ma Y, Yuan H, Zhao D, Meng F. Correction: Wang et al. Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Vaccines 2025, 13, 1024. Vaccines. 2026; 14(1):95. https://doi.org/10.3390/vaccines14010095

Chicago/Turabian Style

Wang, Yanxia, Xiangling Lei, Lili Huang, Yuehong Ma, Hongxue Yuan, Dongyang Zhao, and Fanhong Meng. 2026. "Correction: Wang et al. Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Vaccines 2025, 13, 1024" Vaccines 14, no. 1: 95. https://doi.org/10.3390/vaccines14010095

APA Style

Wang, Y., Lei, X., Huang, L., Ma, Y., Yuan, H., Zhao, D., & Meng, F. (2026). Correction: Wang et al. Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Vaccines 2025, 13, 1024. Vaccines, 14(1), 95. https://doi.org/10.3390/vaccines14010095

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop